Why Is Molecular Residual Disease Becoming the Next Frontier for the U.S. Liquid Biopsy Market?

Cancer management relies on timely detection, accurate risk assessment, and precise post-treatment monitoring. Liquid biopsy platforms initially gained momentum as diagnostic tools for genomic profiling in advanced malignancies. Today, clinical attention is shifting toward longitudinal cancer tracking. At the center of this shift is molecular residual disease (MRD) testing, which detects microscopic disease following surgery or systemic therapy.

Kings Research projects strong growth in the U.S. liquid biopsy market, from USD 1,261.1 million in 2025 to USD 1,419.6 million in 2026 and USD 3,545.3 million by 2033, at a CAGR of 13.79%. This commercial expansion reflects a fundamental change in oncology care: moving from single point-in-time biomarker profiling to continuous post-operative monitoring.

Why Is Molecular Residual Disease Changing the Role of Liquid Biopsy?

Liquid biopsy originally served primary therapeutic selection in patients with late-stage solid tumors. Clinicians used circulating cell-free DNA to identify actionable genomic variants when tissue specimens were insufficient or difficult to retrieve. While this profiling application remains essential, it represents a snapshot of tumor biology at a single moment.

Molecular residual disease testing redefines blood-based assays as continuous monitoring systems. Rather than merely identifying mutations to select an initial targeted drug, MRD evaluation measures persistent microscopic disease after curative-intent surgery or definitive chemoradiation. Detecting persistent somatic signals in peripheral blood allows care teams to evaluate treatment response and establish post-therapeutic trajectory long before physical symptoms appear.

This paradigm shift moves blood-based testing upstream into early-stage disease management. By tracking tumor-derived fragments over weeks, months, or years, healthcare providers gain dynamic insight into systemic status.

What Makes MRD Different From Conventional Cancer Surveillance?

The American Cancer Society projects approximately 2,114,850 new cancer cases in the United States in 2026. Many individuals undergoing curative surgery experience recurrence due to lingering microscopic cells that escape localized surgical resection or systemic adjuvant therapy.

Conventional surveillance relies primarily on radiographic imaging, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), alongside protein biomarkers like carcinoembryonic antigen (CEA) or prostate-specific antigen (PSA). These established methods possess distinct limitations:

• Detection Limits: Imaging technologies require aggregated tissue masses measuring several millimeters to centimeters in diameter before registering a positive signal. Microscopic cellular clusters remain invisible on standard scans.
• Biological Specificity: Elevated protein biomarkers can stem from tissue inflammation, benign hyperplasia, or systemic health factors, leading to equivocal clinical findings.
• Sampling Frequency: Ionizing radiation exposure and imaging costs limit the frequency of standard radiological scans.

In contrast, circulating tumor DNA (ctDNA) molecular residual disease assays measure direct genomic fragments shed into systemic circulation by surviving malignant cells. Detecting tumor-specific somatic mutations in blood provides direct evidence of persistent disease months before structural lesions become visible on standard imaging modalities.

Comparison: Conventional Surveillance vs. Liquid Biopsy for MRD

Why Is ctDNA Becoming the Core Biomarker for MRD Testing?

Circulating tumor DNA comprises short fragments of cell-free nucleic acid released into the bloodstream through apoptosis, necrosis, or active cellular secretion from malignant cells. In patients who complete curative surgery, overall cell-free DNA levels stem primarily from healthy hematopoietic cells. Tumor-derived fragments account for a tiny fraction of total circulating DNA, often present at trace levels in peripheral blood.

In 2025, ctDNA was the largest biomarker segment at 43.45% of the U.S. liquid biopsy market. This dominance stems from the high genomic specificity of ctDNA. Because specific point mutations, insertions, deletions, or structural rearrangements originate exclusively from tumor tissue, identifying these variants in plasma establishes the presence of remaining cancer cells.

Achieving consistent detection at ultralow tumor fractions requires serial blood collection. Repeated longitudinal evaluation increases analytical sensitivity over time, capturing transient elevations in variant allele frequencies before clinical progression.

How Can MRD Testing Influence Treatment Decisions?

MRD testing provides key longitudinal information that clinicians use to personalize post-treatment management strategies:

1. Adjuvant Escalation: Patients showing persistent ctDNA after surgery face high recurrence risks. Identifying positive molecular status allows oncologists to administer adjuvant chemotherapy or immunotherapy promptly.
2. Treatment De-escalation: Patients exhibiting sustained post-operative ctDNA negativity may possess low recurrence risks, allowing care teams to consider reducing treatment toxicity by withholding unnecessary adjuvant regimens.
3. Recurrence Risk Stratification: Post-treatment biomarker levels offer prognostic value, helping clinicians separate high-risk populations from low-risk cohorts.
4. Therapeutic Response Monitoring: Tracking quantitative changes in variant allele fractions during treatment reveals whether an ongoing therapeutic agent successfully suppresses tumor burden.

Prognostic association differs from proven predictive utility. Demonstrating that ctDNA correlates with recurrence risk is simpler than proving that changing treatments based on MRD testing yields superior overall survival outcomes. Clinical trial programs like IMvigor011 continue working to establish predictive validation across various tumor types.

What Does the FDA's 2026 Bladder Cancer Approval Mean for MRD?

On May 15, 2026, the U.S. Food and Drug Administration (FDA) reached a major regulatory landmark for molecular residual disease testing in solid tumors. The agency approved atezolizumab (Tecentriq and Tecentriq Hybreza, a subcutaneous injection formulation combining atezolizumab and hyaluronidase-tqjs, Genentech, Inc.) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy who test positive for ctDNA MRD via an FDA-authorized diagnostic test.

Simultaneously, the FDA granted Premarket Approval (PMA P260004) to Natera's Signatera CDx as the companion diagnostic device to select eligible post-cystectomy MIBC patients.

Key Clinical Trial Evidence: IMvigor011 (NCT04660344)

The FDA decision rested on efficacy data from IMvigor011, a multi-center, randomized, double-blind, placebo-controlled trial sponsored by Genentech evaluating 250 post-cystectomy MIBC patients who showed ctDNA MRD positivity during serial blood monitoring within 12 months after surgery:

• Disease-Free Survival (DFS): Patients treated with atezolizumab achieved a median DFS of 9.9 months (95% CI: 7.2, 12.7) compared to 4.8 months (95% CI: 4.1, 8.3) for placebo, reflecting a hazard ratio of 0.64 (95% CI: 0.47, 0.87; p-value = 0.0047).
• Overall Survival (OS): Median OS reached 32.8 months (95% CI: 27.7, NE) in the atezolizumab cohort versus 21.1 months (95% CI: 14.7, NE) in the placebo group (hazard ratio 0.59; 95% CI: 0.39, 0.90; p-value = 0.0131).

This approval connects diagnostic test results directly to drug eligibility, transforming MRD testing from an informational assay into a required gatekeeper for immunotherapy delivery.

How Are Companion Diagnostics Turning MRD Into a Treatment-Linked Platform?

Companion diagnostic (CDx) designation establishes a clear regulatory and commercial link between a molecular diagnostic test and a specific therapeutic drug. Historically, companion tests focused on identifying targetable driver alterations prior to first-line treatment.

In the post-operative setting, treatment-linked MRD companion diagnostics create an integrated clinical pathway:

• Step 1: Surgical resection of the primary tumor.
• Step 2: Tumor tissue whole-exome sequencing to design a bespoke multiplex PCR assay panel.
• Step 3: Serial testing starting at least 6 weeks after cystectomy and continuing until either a positive test result or completion of the recommended 12-month testing window, per the approved FDA labeling.
• Step 4 (If ctDNA Detected): Signatera CDx positive result triggers initiation of atezolizumab therapy.
• Step 5 (If ctDNA Undetected): Signatera CDx negative result guides continuation of routine serial surveillance.

This integrated pathway provides mutual advantages for diagnostic developers and pharmaceutical manufacturers:

• Pharmaceutical Companies: Linking drug administration to positive biomarker status enriches trial cohorts with high-risk patients who derive clear clinical benefit, improving odds of demonstrating therapeutic efficacy.
• Diagnostic Developers: Securing companion diagnostic status establishes standardized clinical utility, driving reimbursement coverage and routine clinical adoption.

Which Technologies Are Improving the Sensitivity of MRD Detection?

Detecting trace amounts of ctDNA in post-operative blood samples requires exceptional assay sensitivity. Developers use diverse technical approaches to address this challenge:

Technology Comparison Table

Assay design involves balancing analytical limits of detection with specificity. In 2024, FDA guidance emphasized standardized assay performance metrics, including limit of detection, to establish consistent performance across diagnostic platforms.

Can AI and Multiomics Push MRD Beyond Single-Biomarker Testing?

Interpreting multiomic datasets from circulating cell-free DNA requires advanced computational algorithms. Modern diagnostic approaches combine multiple biological layers:

• Fragmentomics: Analyzing length distribution patterns of cell-free DNA fragments, as tumor-derived fragments often show shorter size distributions than healthy cell-free DNA.
• DNA Methylation Profiles: Evaluating hypermethylation patterns at specific promoter sites to identify tissue-of-origin and tumor signals without depending solely on point mutations.
• Artificial Intelligence & Machine Learning: Deploying neural network models trained on high-dimensional genomic features to separate true low-frequency somatic signals from background sequencing artifacts.

In the context of early cancer screening rather than post-treatment monitoring, clinical research conducted by a specific diagnostic developer (where authors disclosed cofounder roles, directorships, and pending patents) indicates that integrating multiple molecular signals with machine-learning approaches can improve liquid biopsy performance. These multi-layered diagnostic platforms remain active targets of ongoing clinical evaluation.

Where Does MRD Still Fall Short in Routine Cancer Care?

Despite clinical progress, MRD assays encounter biological and analytical challenges:

• Low Tumor Shedding: Certain solid malignancies, including central nervous system tumors and renal cell carcinomas, shed minimal cell-free DNA into systemic blood circulation, increasing false-negative rates.
• Biological Variability: Transient biological events, such as post-operative systemic inflammation, physical trauma, or infection, elevate background healthy cell-free DNA, diluting low-abundance tumor signals.
• Clonal Hematopoiesis of Indeterminate Potential (CHIP): Age-related somatic mutations arising in hematopoietic stem cells can mimic tumor-derived variants in plasma, creating potential false-positive calls in tumor-naive assays.
• Tumor Heterogeneity: Clonal evolution during or after treatment can yield recurrent populations lacking original targeted mutations tracked by bespoke assay designs.

Distinguishing analytical detection capability from proven clinical utility remains crucial. Detecting circulating tumor DNA confirms the presence of residual biological signal, but establishing how care teams should act on that signal across every tumor type requires ongoing prospective clinical trial validation.

What Is Slowing the Commercial Adoption of MRD Testing in the U.S.?

Commercial implementation across clinical oncology workflows faces practical operational barriers:

1. Reimbursement Policies: While Medicare Local Coverage Determinations (LCDs) administered through the MolDX program cover select MRD assays for specific indications (such as colorectal cancer and muscle-invasive bladder cancer), commercial payer coverage varies widely. Payers frequently request prospective trial evidence demonstrating improved overall survival before granting broad reimbursement.
2. Turnaround Times: Tumor-informed assay workflows require initial tissue acquisition, exome sequencing, personalized panel design, and custom primer production. This initial setup can require several weeks, which may delay clinical treatment timelines.
3. Tissue Availability: Insufficient tumor tissue can limit genomic profiling, creating a need for less invasive approaches such as liquid biopsy when biopsy samples do not provide adequate material for molecular testing.
4. Physician Adoption & Workflow Integration: Integrating periodic blood draws into busy community oncology practices requires standardized ordering pathways, electronic health record (EHR) integration, and clear interpretative guidance for complex molecular results.

How Is Regulation Shaping the Commercial Pathway for MRD Tests?

The regulatory landscape for oncology diagnostics continues to formalize. In 2024, the FDA Oncology Center of Excellence (OCE) published final guidance regarding circulating tumor DNA use in curative-intent solid tumor drug development. Key regulatory pillars include:

• Analytical Validation: Demonstrating assay precision, limit of detection, and reproducible performance across independent laboratory runs.
• Clinical Validation: Proving the assay reliably identifies the targeted biological phenotype in defined patient populations.
• Patient Selection: Establishing standard validation criteria so diagnostic platforms can serve as patient-selection tools in registration trials. The FDA notes that while ctDNA is not currently validated for use as an early trial endpoint, it may have the potential to serve as one.

Clear regulatory frameworks reduce development risk for diagnostic developers and pharmaceutical sponsors, establishing structured pathways toward companion diagnostic authorization.

Which Companies Are Building Positions in the MRD Ecosystem?

The commercial landscape features specialized diagnostic developers, life science conglomerates, and comprehensive precision oncology providers:

• MRD-Focused Diagnostic Developers: Natera holds a leading regulatory position following the May 2026 FDA Premarket Approval of Signatera CDx as a companion diagnostic for atezolizumab in bladder cancer.
• Precision Oncology and Genomic Testing Leaders: Guardant Health (utilizing Guardant Reveal), Myriad Genetics, NeoGenomics, Caris Life Sciences, and Foundation Medicine continue expanding clinical trial evidence across solid tumor indications.
• Large Diagnostics & Life Science Corporations: Roche, Abbott, Illumina, and Thermo Fisher Scientific support the ecosystem by manufacturing high-throughput sequencing platforms, digital PCR instruments, and standardized assay reagents.

Strategic positioning centers on building clinical trial partnerships with pharmaceutical developers, securing Medicare and commercial reimbursement coverage, and developing multiomic diagnostic platforms.

What Does MRD Mean for the Future of the U.S. Liquid Biopsy Market?

As noted by Kings Research, the U.S. liquid biopsy market is projected to expand from USD 1,419.6 million in 2026 to USD 3,545.3 million by 2033, driven by a 13.79% CAGR.

Molecular residual disease testing plays an increasingly key role in shaping this long-term growth trajectory:

• Shift to Recurring Serial Volume: Baseline diagnostic genomic profiling occurs once or twice per patient care journey. In contrast, post-operative monitoring involves blood collection every 3 to 6 months over several years (or within bounded timeframes, such as the 12-month window for specific indications like MIBC), generating recurring test volumes per patient.
• Expansion into Early-Stage Oncology: Early-stage cancer populations outnumber late-stage, metastatic cohorts. Expanding blood testing into adjuvant and surveillance settings dramatically increases total addressable patient volumes.
• Therapeutic Value Links: Companion diagnostic approvals establish direct links to high-value oncology therapeutics, reinforcing test clinical utility.

Could MRD Become the Bridge Between Diagnosis and Continuous Cancer Management?

Liquid biopsy technology is evolving from a static diagnostic tool into a longitudinal cancer surveillance framework. The clinical journey increasingly follows an integrated continuous pathway moving from initial diagnosis and tissue profiling, through curative surgery, serial ctDNA tracking, and MRD-guided treatment adjustments.

Whether molecular residual disease testing fulfills its potential as a universal care standard depends on continuous progress across three key areas: analytical sensitivity enhancements, broad commercial reimbursement, and prospective clinical trial validation demonstrating overall survival benefits across diverse solid tumor types.

Frequently Asked Questions

What is the difference between MRD and recurrence?

Molecular residual disease (MRD) refers to persistent microscopic tumor fragments in blood that remain after curative surgery or systemic treatment. Recurrence describes macroscopic cancer growth identified through radiographic imaging or tissue biopsy. MRD represents a pre-clinical molecular signal occurring prior to physical recurrence.

How frequently is ctDNA MRD tested?

For the FDA-approved post-cystectomy MIBC pathway, serial testing starts at least 6 weeks after surgery and continues until either a positive test result or completion of the recommended 12-month testing window. In general surveillance contexts, testing protocols typically involve blood draws every 3 to 6 months during the initial 2 to 3 years following curative surgery or therapy. Testing cadence depends on specific tumor characteristics, baseline recurrence risk, applicable clinical trial guidelines, or institutional protocols.

Can MRD testing replace imaging?

Current clinical guidelines view liquid biopsy testing as a complementary tool alongside standard imaging. Blood assays provide molecular risk detection, while radiographic imaging pinpoints specific anatomical lesion locations for surgical or targeted interventions.

Which cancers have the strongest evidence for ctDNA MRD?

Colorectal cancer and muscle-invasive bladder cancer possess extensive clinical evidence supporting ctDNA MRD utility. Active clinical trials continue expanding validation across non-small cell lung, breast, pancreatic, and ovarian malignancies.

What happens after a positive MRD test?

A positive result prompts clinical evaluation. Depending on validated drug indications (such as atezolizumab in post-cystectomy bladder cancer), clinicians may initiate immunotherapy, administer adjuvant chemotherapy, adjust surveillance frequency, or enroll patients in biomarker-driven clinical trials.

Is MRD testing covered by insurance in the U.S.? 

Medicare covers specific MRD assays for select indications through MolDX Local Coverage Determinations. Commercial insurance coverage varies by payer, tumor type, and whether the assay holds FDA companion diagnostic authorization.

As molecular residual disease (MRD) testing shifts blood-based diagnostics toward longitudinal monitoring, staying ahead of competitive and technology trends is crucial. Gain access to detailed market statistics, growth drivers, and strategic insights across the U.S. landscape. Access the complete Kings Research U.S. Liquid Biopsy Market Report to inform your strategic decision-making.